NCT00165230已完成2 期
A Phase II Study of Thalidomide in Combination With Temodar in Patients With Metastatic Neuroendocrine Tumors
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 32
- 试验地点
- 6
- 主要终点
- To assess the response rate in patients with locally unresectable neuroendocrine tumors treated with temodar and thalidomide.
研究概览
简要总结
The purpose of this study is to find out what effects, good or bad, that thalidomide and temodar have on patients with neuroendocrine tumors.
详细描述
- Patients will receive thalidomide orally once daily continuously unless they experience significant side effects. Temodar is given orally once a day for one week, followed by a one week break period. This one week on/one week off schedule will continue for the duration of treatment unless there are significant side effects.
- After eight weeks (2 cycles) a CT scan will be performed to see how the treatment has affected the patient's tumor. Patients will continue taking the study drug unless there is evidence of tumor growth.
- Regular blood tests will be done weekly during the first two months to make sure that the treatment is not resulting in serious side effects. If there are no side effects during the first two months, the blood tests may decrease in frequency to every two weeks.
- Immediately after the patient has completed the study they will be evaluated by physical exam, blood work, and a CT scan. The follow-up will consist of clinic visits and phone calls every 3 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed locally unresectable or metastatic neuroendocrine tumor excluding small cell carcinoma
- •Prior treatment with chemoembolization or cryotherapy is allowed
- •Radiotherapy is allowed if completed more than 4 weeks prior to study.
- •Measurable disease as defined by RECIST criteria
- •Age greater than or equal to 18 years.
- •ECOG performance status of less than or equal to 2
- •ANC >1,500/mm3
- •Platelet Count > 100,000/mm3
- •Hemoglobin > 9 g/dl
- •Serum creatinine < 1.5 x ULN
- •Total bilirubin < 2 x ULN
- •SGOT and SGPT < 2 x ULN
- •Alkaline phosphatase < 2 x ULN
- •Life expectancy of greater than 12 weeks
排除标准
- •Clinically symptomatic central nervous system metastases or carcinomatous meningitis
- •Myocardial infarction in past 6 months
- •Major surgery in past two weeks
- •Uncontrolled serious medical or psychiatric illness
- •Insufficient recovery from all active toxicities of prior therapies
- •Active nonmalignant systemic disease
- •Frequent vomiting or medical condition that could interfere with oral medication intake
- •Known HIV positivity or AIDS-related illness
- •Pregnant or nursing women
结局指标
主要结局
To assess the response rate in patients with locally unresectable neuroendocrine tumors treated with temodar and thalidomide.
次要结局
- To evaluate overall response and progression free survival of this patient population
- to evaluate the safety of temodar and thalidomide.
研究者
研究点 (6)
Loading locations...
相似试验
已完成
2 期
Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to MelanomaRecurrent MelanomaStage IV MelanomaTumors Metastatic to BrainNCT00072163National Cancer Institute (NCI)50
已完成
2 期
Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple MyelomaMultiple MyelomaNCT00538733Weill Medical College of Cornell University26
已完成
2 期
Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and ThalidomideMultiple MyelomaNCT00083382University of Arkansas83
已完成
2 期
Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and ThalidomideMultiple MyelomaNCT00083408University of Arkansas20
终止
2 期
Thalidomide With or Without Fludarabine in Treating Patients With Hematologic CancerRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaNCT00009984National Cancer Institute (NCI)70